



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: +91-40-65523363
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST:36AAACC8372L1ZB

14/02/2018

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Ref: 1. Scrip Code: 524752; Notice of Board meeting Dated 05th February, 2018

Sub: Outcome of Board Meeting – Standalone Unaudited Financial Results for Quarter ended 31st December, 2017

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and all other applicable provisions, this is to inform you that at the meeting of the Board of Directors of the company held today ie; 14th February, 2018 from 2:00 pm to 2:45pm, the Statement of Un-Audited Financial Results for the quarter ended 31st December, 2017 was approved and taken on record along with the Limited Review Report for the period as issued by the Statutory Auditors of the company.

Please find enclosed the following in respect of the above said:

1. Statement of Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 2017 along with the requisite enclosures.
2. Limited Review Report of the Auditors on Quarterly Financial Results.

We kindly request you to take the same on record.

Thanking you
Yours Sincerely
For **COMBAT DRUGS LIMITED**

Sushant Mohan Lal
(DIRECTOR & COMPLIANCE OFFICER)



Encls: as above

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2017

(Rupees in lakhs)

S.No	Particulars	Quarter Ended			9 Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
I	(a) Revenue from operations	15.06	0.00	15.31	18.65	28.23
II	(b) Other Income	28.13	22.90	0.00	51.04	0.00
III	Total Income (I+II)	43.19	22.90	15.31	69.69	28.23
	Expenses					
	a. Cost of materials consumed	12.93	0.00	12.00	13.73	19.70
	b. Employee benefits expense	9.78	7.20	7.02	22.95	16.19
	c. Other expenses	9.52	3.37	1.57	17.49	11.58
IV	Total Expenses	32.23	10.57	20.59	54.17	47.47
V	Profit/(Loss) before Exceptional items & tax (III-IV)	10.96	12.33	(5.28)	15.52	(19.24)
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before tax (V-VI)	10.96	12.33	(5.28)	15.52	(19.24)
VIII	Tax expense					
	a. Current Tax	-	-	-	-	-
	b. Deferred Tax	-	-	-	-	-
IX	Profit/(Loss) for the period (VII-VIII)	10.96	12.33	(5.28)	15.52	(19.24)
X	Other Comprehensive Income					
	A(i) Items that will not be re-classified to profit or loss (Net of Tax)	-	-	-	-	-
	B(i) Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	10.96	12.33	(5.28)	15.52	(19.24)
XII	Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00	800.00
XIII	Earnings per share (EPS)					
	(a) Basic	0.14	0.15	(0.07)	0.19	(0.24)
	(b) Diluted	0.14	0.15	(0.07)	0.19	(0.24)

Notes

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2018. Statutory Auditors have reviewed the above financial results.

2 In terms of Sec.133 of the Companies Act, 2013, the Company has adopted Indian Accounting Standards (Ind AS) w.e.f., 1st April 2017 and accordingly these unaudited financial results have been prepared in accordance with the recognition and measurement principals laid down in Ind AS 34 'Interim Financial Reportign' and other accounting principles generally accepted in India.

3 Reconciliation between financial results as previously reported under IGAAP and Ind AS for the Quarter and Nine months ended 31st Decemeber 2016 is given below:

Particulars	Quarter End 31.12.2016	9 Months End 31.12.2016
Net Profit/(loss) under previous IGAAP	(5.28)	(19.24)
Adjustments as per Ind AS	-	-
Total Comprehensive Income under Ind AS	(5.28)	(19.24)

4 The Company has opted to avail the relaxation provided by SEBI with respect to requirements for submission of IND AS compliant financial results for the previous year ended March 31, 2017. Accordingly, the figures for the financial results for the previous year ended March 31, 2017 have not been presented.

5 The Company is operating in only one segment i.e., Pharmaceuticals and hence segment reporting is not applicable.

6 During the quarter, Company has Invested in 100% Subsidiary in Singapore by name "RA Labs PTE LTD". The Company in accordance with Proviso to Regulation 33(3)(b)(1) of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 has opted to publish only Standalone Results.

For and on behalf of the Board of Directors

Place: Hyderabad
Date : 14.02.2018


MANAGING DIRECTOR

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL STATEMENTS**

To
The Board of Directors of Combat Drugs Limited


We have reviewed the accompanying statement of standalone unaudited financial results of Combat Drugs Limited for the quarter and nine months ended 31st December, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14th February, 2018

For M. Anandam & Co.,
Chartered Accountants
(ERN: 000125S)



A.V. Sadasiva
Partner

Membership No.018404

